In-situ hybridization is a laboratory procedure that allows researchers to locate the position of specific DNA/RNA sequences in chromosomes. Molecular hybridization is based on the ability of DNA helix to re-form or re-nature when provided with favorable conditions. In molecular hybridization technique, a labeled DNA or RNA sequence is utilized as a probe to identify/locate or quantify the naturally occurring DNA or RNA sequence in a biological sample. Nucleic acid probe is synthesized, labeled, purified, and annealed with the specific target. It is an important technique in genetic research and finding gene-based medicine especially in personalized medicine.

In-situ hybridization is classified on the basis of types of probes, fluorescence in-situ hybridization (FISH), in which fluorescence probe is used and chromogenic in-situ hybridization (CISH). FISH allows to visualize multiple targets in the same sample and is primarily applicable for detecting presence of particular gene, number of copies of gene in sample, and mutation analysis. CISH enables to gain genetic information in the context of tissue morphology and is primarily applicable in case of molecular pathology diagnostics.

In-situ Hybridization Market- Dynamics

In situ hybridization, especially FISH which has human applications are principally utilized for clinical diagnosis of chronic diseases such as cancer, immune diseases, and certain rare diseases caused due to chromosome abnormalities. Therefore, rising incidence of cancer globally is expected to be one of the major factors driving growth of the in-situ hybridization market. FISH technique is used to identify mutating gene in patients with the help of dedicated assay kits available from key players.

According to the World Health Organization (WHO) factsheet, 2018, cancer is one of the leading causes of morbidity and mortality worldwide, with around 14 million new cases in 2012 and death of around 8.8 million people in 2012.

Furthermore, rising efforts in the field of genetic research, genetic diagnosis, and gene-based medicine would propel growth of in-situ hybridization market. For instance, personalized medicine such as CAR-T cell therapies are increasingly focused by companies to find cure for cancer. Future risk associated with disease can be traced with gene-based detection of which is gaining traction in the market. In April 2018, PerkinElmer, Inc. and Helix (personal genomics company) announced collaboration to develop and commercialize exome sequencing-based diagnosis tests, which can locate specific genes in a sample.

In-situ Hybridization Market- Regional Insights

On the basis of geography, the global in-situ hybridization market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the in-situ hybridization market over the forecast period. U.S. has high incidence of different types of cancer. According to the American Cancer Society factsheet published in 2018, cancer is the second leading cause of death after cardio vascular disease. Furthermore, around 1.7 million new cancer cases and over half million death is projected to occur in 2018.  Moreover, the presence of key players that supplies advanced assay kits and probes for diagnostic and research and development activities in the U.S. would boost growth of the market in this region.

In-Situ Hybridization Market- Competitive Landscape

Key players operating in the global in-situ hybridization market include Abbott Laboratories, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Merck KGaA, PerkinElmer, Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories, Inc., Advanced Cell Diagnostics, Inc., and Bio SB Inc.

Key players are launching new products in in-situ hybridization market.

  • In June 2018, Agilent Technologies Inc. launched a new FISH and CISH probes for in-situ hybridization. The new probes address the need to cleanly and accurately interpret data from both fluorescence in-situ hybridization (FISH) and chromogenic in-situ hybridization (CISH).
  • In 2016, Oxford Gene Technology, which is a molecular genetics company, launched two new CE-IVD labelled fluorescence in-situ hybridization (FISH) probes, further expanding for lung cancer diagnosis. The Cytocell Aquarius ROS1 Plus Breakapart and RET Breakapart probes specifically and accurately detect rearrangements in the genome associated with non-small cell lung cancer.

In-Situ Hybridization Market- Taxonomy

On the basis of product, the global in-situ hybridization market is segmented into:

  • Assay Kits and Probes
  • Reagents
  • Instruments

On the basis of hybridization technique, the global in-situ hybridization market is segmented into:

  • Fluorescence In Situ Hybridization
  • Chromogenic In Situ Hybridization

On the basis of application, the global in-situ hybridization market is segmented into:

  • Cancer Diagnosis
  • Cytogenetics
  • Developmental Biology
  • Infectious Diseases
  • Immunology
  • Others

On the basis of end user, the global in-situ hybridization market is segmented into:

  • Research and Academic Institutes ,
  • Diagnostic laboratories
  • Pharmaceutical and Biotech Companies
  • Others

On the basis of geography, the global in-situ hybridization market is segmented into:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
N/A
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner